Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong revenue guidance with a raised outlook, optimistic backlog conversion, and a strategic shift to faster growing therapeutic areas. Despite slower EBITDA growth, the overall sentiment is positive due to improved funding confidence, a strong pre-backlog position, and expected acceleration in hiring. While some uncertainties remain, particularly around cancellations and competition, the positive aspects outweigh them, suggesting a likely stock price increase over the next two weeks.
Key Financial Performance
Revenue (Q3 2025) $659.9 million, a year-over-year increase of 23.7%. The increase was favorably impacted by higher reimbursable cost activity, particularly investigator sites, driven by a therapeutic mix shift to faster burning studies in areas with a higher concentration of reimbursable costs.
Net New Business Awards (Q3 2025) $789.6 million, a year-over-year increase of 47.9%. This resulted in a 1.20 net book-to-bill ratio.
Ending Backlog (as of September 30, 2025) Approximately $3 billion, an increase of 2.5% from the prior year.
EBITDA (Q3 2025) $148.4 million, a year-over-year increase of 24.9% compared to $118.8 million in Q3 2024. The increase was driven by productivity and lower employee-related costs, offset by higher reimbursable costs.
EBITDA Margin (Q3 2025) 22.5%, compared to 22.3% in the prior year period. Margins benefited from productivity and lower employee-related costs, offset by higher reimbursable costs.
Net Income (Q3 2025) $111.1 million, a year-over-year increase of 15.3% compared to $96.4 million in Q3 2024. Growth was below EBITDA growth due to a higher effective tax rate and lower interest income.
Net Income Per Diluted Share (Q3 2025) $3.86, compared to $3.01 in the prior year period.
Cash Flow from Operating Activities (Q3 2025) $246.2 million.
Net Days Sales Outstanding (Q3 2025) Negative 64.3 days.
Share Repurchases (Q3 2025) Approximately 14,649 shares for $4.5 million. Year-to-date, 2.96 million shares were repurchased for $912.9 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue Growth: Revenue in Q3 2025 was $659.9 million, a 23.7% year-over-year increase. Revenue for the first nine months of 2025 was $1.82 billion, up 15.9%.
Backlog Growth: Ending backlog as of September 30, 2025, was approximately $3 billion, a 2.5% increase from the prior year. Approximately $1.84 billion of backlog is expected to convert to revenue in the next 12 months.
Net New Business Awards: Net new business awards in Q3 2025 increased 47.9% year-over-year to $789.6 million, resulting in a net book-to-bill ratio of 1.20.
EBITDA Growth: EBITDA in Q3 2025 was $148.4 million, a 24.9% increase from Q3 2024. Year-to-date EBITDA was $397.5 million, up 14.7%.
EBITDA Margin: EBITDA margin for Q3 2025 was 22.5%, slightly higher than 22.3% in Q3 2024. Year-to-date EBITDA margin was 21.8%, compared to 22% in the prior year.
Net Income: Net income in Q3 2025 was $111.1 million, a 15.3% increase from Q3 2024. Net income per diluted share was $3.86, compared to $3.01 in Q3 2024.
Cash Flow: Generated $246.2 million in cash flow from operating activities in Q3 2025.
Share Repurchase Program: Repurchased approximately 14,649 shares for $4.5 million in Q3 2025. Year-to-date repurchases totaled 2.96 million shares or $912.9 million. $821.7 million remains under the share repurchase authorization program.
2025 Guidance Update: Full-year 2025 revenue is expected to range from $2.48 billion to $2.53 billion, representing 17.6% to 20% growth over 2024. EBITDA is projected to range from $545 million to $555 million, reflecting 13.5% to 15.6% growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cancellations: While cancellations were 'well behaved' in Q3, there is an implied risk that cancellations could increase in the future, potentially impacting net bookings and revenue.
Pass-through costs: Pass-through costs are expected to remain high, representing 41%-42% of revenue. This could pressure margins and profitability if not managed effectively.
Customer concentration: The top 5 and top 10 customers represent 23% and 33% of year-to-date revenue, respectively. This concentration poses a risk if any of these customers reduce or terminate their business with the company.
Tax rate and interest income: Net income growth was below EBITDA growth due to a higher effective tax rate and lower interest income, which could continue to impact profitability.
Backlog conversion: Backlog conversion was 23% of beginning backlog in Q3. If conversion rates slow, it could delay revenue realization and impact financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Growth: Anticipated to grow in a low double-digit range off the updated 2025 full-year guidance.
2026 EBITDA Growth: Expected to grow at a high single-digit pace or greater.
Pass-Through Costs: Projected to remain high compared to historical levels, representing between 41% and 42% of revenue.
Backlog Conversion: Approximately $1.84 billion of backlog is projected to convert to revenue in the next 12 months.
2025 Revenue Guidance: Full-year revenue expected in the range of $2.48 billion to $2.53 billion, representing growth of 17.6% to 20% over 2024.
2025 EBITDA Guidance: Expected in the range of $545 million to $555 million, representing growth of 13.5% to 15.6% compared to 2024.
2025 Net Income Guidance: Forecasted in the range of $431 million to $439 million.
2025 Earnings Per Share (EPS): Expected to be in the range of $14.60 to $14.86.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: During the quarter, we repurchased approximately 14,649 shares for $4.5 million. Year-to-date, we repurchased 2.96 million shares or $912.9 million. As of September 30, 2025, we had $821.7 million remaining under our share repurchase authorization program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the pass-throughs in relation to the increase in metabolic work and the leveling off of the higher metabolic mix?
A:Pass-throughs are expected to peak in Q4 2025 and come down over 2026. The increase in metabolic work is a significant driver, but other factors like timing of projects and the backloading of pass-through costs in trials also contribute. New studies incur greater direct costs earlier, while pass-through costs are incurred later in the trial.
Q:Why is EBITDA growing lower than revenue, and what is the impact of the pricing environment?
A:The lower EBITDA growth is primarily due to the pass-through dynamic. Other factors include exchange rates and industry challenges. The pricing environment has seen increased focus due to industry slowdown, but pricing is not expected to drive meaningful changes in margins.
Q:How do you think about the conversion rate of pre-backlog and its impact on FY 2026?
A:The pre-backlog bucket of awarded work is up 30% year-over-year and is larger than the backlog itself. This positions the company well for refilling the backlog and revenue generation in 2026, reducing concerns about a potential air gap in revenue growth.
Q:Why is the timing dynamic different for Medpace compared to peers regarding activity levels and funding impacts?
A:The difference is driven by cancellations rather than weak business. Despite cancellations, the pre-backlog bucket grew by 30% over the last year, indicating a strong underlying business environment.
Q:How will the business evolve in terms of backlog growth, burn rate, and hiring?
A:Backlog is expected to grow faster, burn rate to come down, and hiring to accelerate to support growth. Most recent hiring has been in the U.S., with significant growth in India within Asia Pacific.
Q:What are the expectations for book-to-bill and bookings growth in Q4 2025 and 2026?
A:The company targets a book-to-bill ratio of 1.15 for Q4 2025. However, no specific guidance for 2026 bookings was provided. The pre-backlog bucket is up 30%, but the exact impact on bookings growth remains uncertain.
Q:How have decision-making timelines and funding confidence changed recently?
A:Decision-making timelines have normalized compared to earlier in 2025, with fewer delays and improved funding confidence among clients. However, some clients still face funding challenges.
Q:What are the assumptions underlying the preliminary 2026 growth expectations?
A:The assumptions include a business environment similar to Q3 2025, with most of the 2026 pipeline already in place. Cancellations are the biggest wild card, but the company assumes a cancellation rate slightly higher than recent quarters but lower than earlier peaks.
Q:What are the trends in margins for the core direct service revenue business?
A:Margins are expected to remain strong in 2026, driven by improved productivity, low attrition rates, and good utilization levels. The company does not expect significant changes outside of the pass-through impact.
Q:Was the Q3 2025 revenue growth driven by a narrow set of customers or broader factors?
A:The revenue growth was broad-based, influenced by increased pass-throughs and improved funding, with fewer cancellations and better study progression.
Q:Will headcount growth need to accelerate to support 2026 sales forecasts?
A:Yes, headcount growth is expected to accelerate in 2026 to support sales forecasts.
Q:Are larger CROs entering Medpace's market, and how is competition affecting win rates?
A:Larger CROs have always been competitors, and there is no trend of increased competition affecting win rates. The company’s competitive position remains strong, although more providers are being invited to opportunities, slightly reducing win rates.
Q:What is the outlook for burn rate trends in the coming years?
A:Burn rate trends depend on the mix of programs and their life cycle stages. It is influenced by bookings and the progression of programs from awards to backlog.
Q:How does the therapeutic mix of the pre-backlog compare to current revenue?
A:The pre-backlog is over-indexed in metabolic studies compared to current revenue, aligning with the company's focus on metabolic work.
Q:What is the size and significance of the pre-backlog bucket?
A:The pre-backlog bucket is slightly under $4 billion and represents firm awarded work that has not yet reached the first patient stage. It is a significant part of the pipeline but carries higher risk than backlog.
Q:What is the impact of GLP-1 drugs on the metabolic segment?
A:GLP-1 drugs account for approximately two-thirds of the obesity-related metabolic segment, with the remainder being other metabolic studies.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026 bookings and revenue growth, particularly regarding the exact size of the pre-backlog bucket and its conversion to backlog. They also did not clarify the long-term burn rate trends or provide detailed metrics on award sizes and win rates. Additionally, they used vague language when discussing the impact of cancellations and the competitive landscape, avoiding precise data or forecasts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Associate Director
Cancellations record
Conference Instructions
Director Investors
Instructions reminder
Investors Relations
Medpace Conference
President CFO
RFP quality
Relations factor
Troendle
analyst model
attempt divergence
backlog basis
backlog increase
basis progress
bill RFP
booking book
change today
day Cancellations
decision tempo
digit pace
divergence view
dollar value
estimate Associate
expectation change
level comment
model digit
notification dollar
opportunity result
pace level
progress opportunity
record booking
result view
tempo award
value work
view analyst
view attempt
work backlog
MEDP Transcript
Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript
Unknown2-10
The earnings call presented a mixed picture: strong revenue growth expectations were offset by high cancellation rates and unclear management responses on key issues like AI impact and M&A environment. While product development and market strategy showed some positive signs, concerns over pass-through costs and the lack of specific guidance on cancellation trends and burn rate create uncertainties. The absence of a new partnership announcement or major shareholder return plan further tempers positive sentiment, resulting in a neutral outlook for the stock price over the next two weeks.
Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript
Positive10-23
The earnings call summary indicates strong revenue guidance with a raised outlook, optimistic backlog conversion, and a strategic shift to faster growing therapeutic areas. Despite slower EBITDA growth, the overall sentiment is positive due to improved funding confidence, a strong pre-backlog position, and expected acceleration in hiring. While some uncertainties remain, particularly around cancellations and competition, the positive aspects outweigh them, suggesting a likely stock price increase over the next two weeks.
Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript
Unknown7-22
The earnings call summary indicates mixed signals: improved backlog growth and low cancellations are positive, but the weak win rate and dependency on low cancellations for future success are concerning. The Q&A reveals management's reluctance to provide specific long-term guidance, adding uncertainty. Despite improved productivity and revenue growth, reliance on pass-through revenue and potential headwinds in 2025 suggest caution. These factors, combined with management's vague responses, lead to a neutral sentiment, anticipating minimal stock price movement.
Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2025 Earnings Call Transcript
Unknown4-23
The earnings call reveals concerns about increased price competition, mixed project quality, and reliance on a few customers. EBITDA margins are decreasing, and there is uncertainty in backlog growth and bookings due to cancellations. Despite share repurchases, the Q&A highlights risks like funding issues and lack of clear guidance. These factors, combined with a decrease in net new business awards, suggest a negative sentiment likely affecting stock price.
MEDP Slides
MEDP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
